US7612199B2
Active / In Force
US
⏱️ 2.6 years remaining
Polymorphic forms α, β, and γ of rifaximin
Assignee: Alfasigma SpA
•
Filing: 2009-06-04
•
Granted: 2009-11-03
•
Expires: 2029-06-04
Abstract
Abstract Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
Inventors
- 👤 Guiseppe Glaudio VISCOMI
- 👤 Manuela Campana
- 👤 Dario Braga
- 👤 Donatella Confortini
- 👤 Vicenzo CANNATA
- 👤 Paolo Righi
- 👤 Goffredo Rosini
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 14:23
CPC Classifications
C; C07; C07D; C07D498/00; C07D498/22; C07D491/00; C07D491/22; C07B; C07B2200/00; C07B2200/13
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
34 words
Rifaximin in polymorphic form α, wherein the rifaximin has x-ray powder diffraction pattern peaks at about 7.4°; 19.7°; 21.0° and 22.1° 2-θ and wherein the rifaximin has a water content of less than 4.5%.
Claim 2
Dependent Claim
34 words
Rifaximin in polymorphic form α, wherein the rifaximin has x-ray powder diffraction pattern peaks at about 7.4°; 19.7°; 21.0° and 22.1° 2-θ and wherein the rifaximin has a water content of less than 4.5%.
Claim 3
Dependent Claim
16 words
The compound of claim 1 , wherein the rifaximin has a water content of between 2.0-3.0%.
Claim 4
Dependent Claim
15 words
The compound of claim 1 , wherein the rifaximin has a water content of 2.5%.
Claim 5
Dependent Claim
32 words
Rifaximin in polymorphic form β, wherein the rifaximin has x-ray powder diffraction pattern peaks at about 5.4°; 9.0°; and 20.9°2θ and wherein the rifaximin has a water content of greater than 5%.
Claim 6
Dependent Claim
32 words
Rifaximin in polymorphic form β, wherein the rifaximin has x-ray powder diffraction pattern peaks at about 5.4°; 9.0°; and 20.9°2θ and wherein the rifaximin has a water content of greater than 5%.
Claim 7
Dependent Claim
16 words
The compound of claim 4 , wherein the rifaximin has a water content of between 5.0-6.0%.
Claim 8
Dependent Claim
34 words
Rifaximin in polymorphic form γ, wherein the rifaximin has x-ray powder diffraction pattern peaks at about 5.0°, 7.1°, and 8.4°2-θ and wherein the rifaximin has a water content of from between 0% to 2%.
Claim 9
Dependent Claim
34 words
Rifaximin in polymorphic form γ, wherein the rifaximin has x-ray powder diffraction pattern peaks at about 5.0°, 7.1°, and 8.4°2-θ and wherein the rifaximin has a water content of from between 0% to 2%.
Claim 10
Dependent Claim
15 words
The compound of claim 6 , wherein the rifaximin has a water content of 1.5%.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2012-11-02 | 2013-05-04 | 2013-11-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2016-11-02 | 2017-05-04 | 2017-11-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2020-11-02 | 2021-05-04 | 2021-11-03 | $7700.00 | Window Closed / Lapsed |